- Home
- IBG vs CPHI Comparison
IBG vs CPHI Comparison
Compare IBG & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- CPHI
- Stock Information
- Founded
- IBG 2018
- CPHI N/A
- Country
- IBG Australia
- CPHI China
- Employees
- IBG N/A
- CPHI N/A
- Industry
- IBG Beverages (Production/Distribution)
- CPHI Biotechnology: Pharmaceutical Preparations
- Sector
- IBG Consumer Staples
- CPHI Health Care
- Exchange
- IBG Nasdaq
- CPHI Nasdaq
- Market Cap
- IBG 5.4M
- CPHI 5.3M
- IPO Year
- IBG 2024
- CPHI N/A
- Fundamental
- Price
- IBG $0.73
- CPHI $1.49
- Analyst Decision
- IBG Strong Buy
- CPHI
- Analyst Count
- IBG 1
- CPHI 0
- Target Price
- IBG N/A
- CPHI N/A
- AVG Volume (30 Days)
- IBG 6.2M
- CPHI 110.1K
- Earning Date
- IBG 08-19-2025
- CPHI 08-18-2025
- Dividend Yield
- IBG N/A
- CPHI N/A
- EPS Growth
- IBG N/A
- CPHI N/A
- EPS
- IBG N/A
- CPHI N/A
- Revenue
- IBG $2,931,243.00
- CPHI $4,295,377.00
- Revenue This Year
- IBG N/A
- CPHI N/A
- Revenue Next Year
- IBG N/A
- CPHI N/A
- P/E Ratio
- IBG N/A
- CPHI N/A
- Revenue Growth
- IBG N/A
- CPHI N/A
- 52 Week Low
- IBG $0.44
- CPHI $1.20
- 52 Week High
- IBG $3.35
- CPHI $3.35
- Technical
- Relative Strength Index (RSI)
- IBG N/A
- CPHI 34.05
- Support Level
- IBG N/A
- CPHI $1.38
- Resistance Level
- IBG N/A
- CPHI $1.63
- Average True Range (ATR)
- IBG 0.00
- CPHI 0.14
- MACD
- IBG 0.00
- CPHI -0.03
- Stochastic Oscillator
- IBG 0.00
- CPHI 19.09
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.